These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution. Steuber H; Heine A; Klebe G J Mol Biol; 2007 May; 368(3):618-38. PubMed ID: 17368668 [TBL] [Abstract][Full Text] [Related]
3. Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A. Howard EI; Sanishvili R; Cachau RE; Mitschler A; Chevrier B; Barth P; Lamour V; Van Zandt M; Sibley E; Bon C; Moras D; Schneider TR; Joachimiak A; Podjarny A Proteins; 2004 Jun; 55(4):792-804. PubMed ID: 15146478 [TBL] [Abstract][Full Text] [Related]
4. Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. El-Kabbani O; Darmanin C; Schneider TR; Hazemann I; Ruiz F; Oka M; Joachimiak A; Schulze-Briese C; Tomizaki T; Mitschler A; Podjarny A Proteins; 2004 Jun; 55(4):805-13. PubMed ID: 15146479 [TBL] [Abstract][Full Text] [Related]
6. Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations. Sotriffer CA; Krämer O; Klebe G Proteins; 2004 Jul; 56(1):52-66. PubMed ID: 15162486 [TBL] [Abstract][Full Text] [Related]
7. Evidence for a novel binding site conformer of aldose reductase in ligand-bound state. Steuber H; Zentgraf M; La Motta C; Sartini S; Heine A; Klebe G J Mol Biol; 2007 May; 369(1):186-97. PubMed ID: 17418233 [TBL] [Abstract][Full Text] [Related]
8. Tracing the detail: how mutations affect binding modes and thermodynamic signatures of closely related aldose reductase inhibitors. Koch C; Heine A; Klebe G J Mol Biol; 2011 Mar; 406(5):700-12. PubMed ID: 21185307 [TBL] [Abstract][Full Text] [Related]
9. High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group. Steuber H; Zentgraf M; Podjarny A; Heine A; Klebe G J Mol Biol; 2006 Feb; 356(1):45-56. PubMed ID: 16337231 [TBL] [Abstract][Full Text] [Related]
10. The alrestatin double-decker: binding of two inhibitor molecules to human aldose reductase reveals a new specificity determinant. Harrison DH; Bohren KM; Petsko GA; Ringe D; Gabbay KH Biochemistry; 1997 Dec; 36(51):16134-40. PubMed ID: 9405046 [TBL] [Abstract][Full Text] [Related]
11. Virtual screening for inhibitors of human aldose reductase. Kraemer O; Hazemann I; Podjarny AD; Klebe G Proteins; 2004 Jun; 55(4):814-23. PubMed ID: 15146480 [TBL] [Abstract][Full Text] [Related]
12. Structure of human aldose reductase holoenzyme in complex with statil: an approach to structure-based inhibitor design of the enzyme. El-Kabbani O; Ramsland P; Darmanin C; Chung RP; Podjarny A Proteins; 2003 Feb; 50(2):230-8. PubMed ID: 12486717 [TBL] [Abstract][Full Text] [Related]
13. The crystallographic structure of the aldose reductase-IDD552 complex shows direct proton donation from tyrosine 48. Ruiz F; Hazemann I; Mitschler A; Joachimiak A; Schneider T; Karplus M; Podjarny A Acta Crystallogr D Biol Crystallogr; 2004 Aug; 60(Pt 8):1347-54. PubMed ID: 15272156 [TBL] [Abstract][Full Text] [Related]
14. Merging the binding sites of aldose and aldehyde reductase for detection of inhibitor selectivity-determining features. Steuber H; Heine A; Podjarny A; Klebe G J Mol Biol; 2008 Jun; 379(5):991-1016. PubMed ID: 18495158 [TBL] [Abstract][Full Text] [Related]
15. Charge-density analysis of a protein structure at subatomic resolution: the human aldose reductase case. Guillot B; Jelsch C; Podjarny A; Lecomte C Acta Crystallogr D Biol Crystallogr; 2008 May; 64(Pt 5):567-88. PubMed ID: 18453693 [TBL] [Abstract][Full Text] [Related]
16. The atomic resolution structure of human aldose reductase reveals that rearrangement of a bound ligand allows the opening of the safety-belt loop. Biadene M; Hazemann I; Cousido A; Ginell S; Joachimiak A; Sheldrick GM; Podjarny A; Schneider TR Acta Crystallogr D Biol Crystallogr; 2007 Jun; 63(Pt 6):665-72. PubMed ID: 17505104 [TBL] [Abstract][Full Text] [Related]
17. Structure of aldehyde reductase in ternary complex with a 5-arylidene-2,4-thiazolidinedione aldose reductase inhibitor. Carbone V; Giglio M; Chung R; Huyton T; Adams J; Maccari R; Ottana R; Hara A; El-Kabbani O Eur J Med Chem; 2010 Mar; 45(3):1140-5. PubMed ID: 20036445 [TBL] [Abstract][Full Text] [Related]
18. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase. Fournier B; Bendeif el-E; Guillot B; Podjarny A; Lecomte C; Jelsch C J Am Chem Soc; 2009 Aug; 131(31):10929-41. PubMed ID: 19594152 [TBL] [Abstract][Full Text] [Related]
19. Aldose and aldehyde reductases: structure-function studies on the coenzyme and inhibitor-binding sites. El-Kabbani O; Old SE; Ginell SL; Carper DA Mol Vis; 1999 Sep; 5():20. PubMed ID: 10493777 [TBL] [Abstract][Full Text] [Related]
20. Structural features of the aldose reductase and aldehyde reductase inhibitor-binding sites. El-Kabbani O; Wilson DK; Petrash M; Quiocho FA Mol Vis; 1998 Sep; 4():19. PubMed ID: 9756955 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]